Back to search results

Elecoglipron for Type 2 Diabetes and Impaired Kidney Function

This study is looking into a new medication called elecoglipron for adults with type 2 diabetes and kidney problems. You would already be taking dapagliflozin (an SGLT2 inhibitor) and other diabetes medications. The study aims to see how well elecoglipron works and if it's safe compared to a placebo (an inactive pill). We will measure changes in your A1c (a measure of blood sugar control) over about 40 weeks to see if elecoglipron helps. To join, you need to be at least 18 years old, have type 2 diabetes for at least 90 days, and have an A1c within a certain range. The current status of this study is unclear, but it plans to enroll around 900 people.

Study design
This study compares elecoglipron to a placebo, with participants taking one or the other once daily. It plans to enroll about 900 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures changes from baseline to Week 40, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07662135

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Recruiting
PHASE3Ages 18+InterventionalTreatment
AstraZeneca
~900 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:ElecoglipronPlacebo

At a glance

Recruiting sites
6 of 185 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in Hemoglobin A1c (HbA1c)
Measured over Baseline to Week 40

Conditions

Type 2 Diabetes Mellitus
Type 2 Diabetes With Chronic Kidney Disease

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

185 sites across 34 states
Germany18
Japan16
China15
India12
Spain12
Taiwan11
Mexico10
Ukraine10

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)
HbA1c value:
Impaired renal function
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion

Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (New York Heart Association IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

What this trial measures

  • Change from baseline in Hemoglobin A1c (HbA1c)Baseline to Week 40